{"id":"anti-cd22-car-nk-cells","phase":"phase_1","safety":{"commonSideEffects":[{"rate":"null","effect":"Cytokine release syndrome"},{"rate":"null","effect":"Neutropenia"},{"rate":"null","effect":"Anemia"}]},"status":"active","trials":["NCT03692767"],"aliases":[],"patents":[],"pricing":[],"timeline":[],"aiSummary":"Targeting CD22 on B cells Used for B-cell malignancies.","brandName":"Anti-CD22 CAR NK Cells","companyId":"allife-medical-science-and-technology-co-ltd","mechanism":{"_ai_source":"groq-llama-8b","explanation":"Anti-CD22 CAR NK Cells are a type of immunotherapy that uses genetically modified natural killer cells to target and destroy cancer cells expressing CD22.","oneSentence":"Targeting CD22 on B cells","_ai_confidence":"medium"},"commercial":null,"companyName":"Allife Medical Science and Technology Co., Ltd.","competitors":[],"genericName":"Anti-CD22 CAR NK Cells","indications":{"approved":[{"name":"B-cell malignancies"}]},"labelChanges":[],"trialDetails":[],"manufacturing":[],"administration":{"icon":"","route":"","frequency":"","formulation":""},"formularyStatus":[],"apiManufacturers":[],"developmentCodes":[],"ownershipHistory":[],"biosimilarFilings":[],"firstApprovalDate":"","companionDiagnostics":[],"firstApprovalCountry":null,"rwe":[],"genericFilers":[],"relatedDrugs":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"modality":"Biologic","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":false,"score":3}}